

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM349291

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	CHANGE OF NAME		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
APPLIED BIOSYSTEMS/MDS SCIEX INSTRUMENTS		01/31/2008	PARTNERSHIP: CANADA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	APPLIED BIOSYSTEMS/MDS ANALYTICAL TECHNOLOGIES INSTRUMENTS		
<b>Street Address:</b>	2810 Matheson Blvd. East, Suite 500		
<b>City:</b>	Mississauga, Ontario		
<b>State/Country:</b>	CANADA		
<b>Postal Code:</b>	L4W 4V9		
<b>Entity Type:</b>	PARTNERSHIP: CANADA		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2917905	PHOTOSPRAY	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2026725399		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	414.297.5745		
<b>Email:</b>	IPdocketing@foley.com, jgreene@foley.com, dfrenkel@foley.com, sschoepfer@foley.com		
<b>Correspondent Name:</b>	Dayna M. Frenkel		
<b>Address Line 1:</b>	Washington Harbour		
<b>Address Line 2:</b>	3000 K Street, N.W., Suite 600		
<b>Address Line 4:</b>	Washington, D.C. 20007-5109		
<b>ATTORNEY DOCKET NUMBER:</b>	099899-0135		
<b>NAME OF SUBMITTER:</b>	Dayna M. Frenkel		
<b>SIGNATURE:</b>	/Dayna M. Frenkel/		
<b>DATE SIGNED:</b>	07/27/2015		
<b>Total Attachments: 5</b>			
source=Change of Name#page1.tif			
source=Change of Name#page2.tif			

OP \$40.00 2917905

source=Change of Name#page3.tif

source=Change of Name#page4.tif

source=Change of Name#page5.tif

SECOND NAME CHANGE AMENDMENT

THIS AMENDMENT to the EXTENDED, AMENDED AND RESTATED JOINT VENTURE AGREEMENT and RELATED AGREEMENTS (the "JV Amendments") is made as of the 31<sup>st</sup> day of January, 2008 ("Effective Date").

AMONG:

APPLIED BIOSYSTEMS (CANADA) LIMITED

With offices at Commerce Court West, Suite 4900, Toronto, ON M5L 1J3,  
Canada  
("AB")

- and -

APPLERA CORPORATION (the successor of PE Corporation (NY)),

Through its APPLIED BIOSYSTEMS GROUP

With offices at 301 Merritt 7, Norwalk, Connecticut 06853, USA  
("Applera")

- and -

MDS INC. through its business unit MDS Analytical Technologies  
(formerly the MDS SCIEX DIVISION)

With business unit offices at 71 Four Valley Drive, Concord, Ontario,  
L4K 4V8, Canada  
("MDS")

- and -

APPLIED BIOSYSTEMS/MDS SCIEX INSTRUMENTS

An Ontario partnership between AB and MDS  
(the "Partnership")

Each a "Party" and collectively, the "Parties".

RECITALS:

AB, Applera and MDS entered into an Extended, Amended and Restated Joint Venture Agreement dated October 1, 2001, as amended (the "Joint Venture Agreement").

The Parties entered into a Technology License Agreement dated October 1, 2001, as amended (the "Technology License Agreement").

MDS and the Partnership entered into a Purchase Agreement dated October 1, 2001, as amended (the "Purchase Agreement").

Applera and the Partnership entered into a Distribution Agreement dated October 1, 2001, as amended (the "Distribution Agreement").

Appiera, MDS and the Partnership entered into a Services Agreement dated October 1, 2001, as amended (the "Services Agreement").

The Parties entered into a Name Change Amendment date July 7, 2000.

AB, Appiera, MDS and the Partnership entered into an Amendment to the Joint Venture Agreement dated October 22, 2004 (Amendment No. 1).

All of the foregoing agreements and amendments are collectively the "JV Partnership Agreements".

MDS has made certain changes in their business and division names, and as part of such changes, it has changed the name under which its MDS Sciex Division conducts business from "MDS Sciex" to "MDS Analytical Technologies" (the "New Name").

AB and MDS now desire to change the name of the Partnership to incorporate the New Name.

NOW, THEREFORE, in consideration of the mutual covenants contained herein and of other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the Parties hereby agree as follows:

1. Amendment to Section 2.1 of the Joint Venture Agreement which reads:

"The name under which the Partnership will conduct business shall be Applied Biosystems/MDS Sciex Instruments and the Partners shall forthwith cause the Partnership to be registered under that name under the applicable laws of all relevant jurisdictions."

Is hereby deleted and replaced with:

"The name under which the Partnership will conduct business shall be Applied Biosystems/MDS Analytical Technologies Instruments and the Partners shall forthwith cause the Partnership to be registered under that name under the applicable laws of all relevant jurisdictions."

2. Registration.

MDS agrees to cause the Partnership to make such governmental registrations, authorizations, permits or other filings (or amendments to existing registrations, authorizations, permits or other filings) in such jurisdictions as are necessary to give effect to the change in the name of the Partnership as contemplated by Section 1 above and to enable the Partnership to conduct business lawfully under the name "Applied Biosystems/MDS Analytical Technologies Instruments" in the jurisdictions where the Partnership conducts business. The costs and expenses of the foregoing actions shall be for the account of the Partnership, and the Partnership shall promptly

reimburse MDS for any such costs and expenses reasonably incurred by them in taking such actions.

3. Trademark Matters.

The Partnership and AB acknowledge and agree that the New Name is a trademark of MDS and/or its affiliates (other than the Partnership) and that the Partnership's rights to and use of that name for any and all purposes is strictly by license as a "Sciex Trademark" under, and pursuant to the terms and conditions of, the Technology License Agreement dated October 31, 1986, as amended. The Partnership and Sciex shall execute such other instruments and take such other actions as may be reasonably requested by MDS to give effect to the intent of this Section 3 under any applicable laws or regulations.

4. Miscellaneous.

This Agreement, together with the JV Partnership Agreements, all as amended to date in writing, constitutes the entire and sole agreement and understanding among the Parties with respect to the subject matter hereof and supersedes any prior or contemporaneous understanding, agreement, representation or warranty, whether written or oral, with respect to the subject matter hereof. Without limitation of the foregoing, this Agreement expressly supersedes any prior agreements or understandings between or among the Parties, whether written or oral, regarding the choice of the name of the Partnership. Except as expressly provided for in this Agreement, the JV Partnership Agreements shall remain in full force and effect in all respects without amendment or modifications. The headings of this Agreement are inserted for the convenience of the parties only and in no way limit, define, or construe the terms of the Agreement. This Agreement shall be governed by and construed in accordance with the law of Ontario, Canada.

IN WITNESS WHEREOF the Parties have executed this Agreement as of the date first above written.

*[Signature Page(s) to follow]*

APPLIED BIOSYSTEMS (CANADA)  
LIMITED

By: [Signature]  
Name: ~~Laura Lauman~~ Dennis L. Winger  
Title: President

Approved for Signature  
by [Signature]  
date 2/1/88  
Applied Biosystems Group  
Legal Department

APPLERA CORPORATION through its  
APPLIED BIOSYSTEMS GROUP


By: [Signature]  
Name: Laura Lauman  
Title: President, P&M

MDS ANALYTICAL TECHNOLOGIES  
through its SCIEX Division (formerly MDS  
Sciex)


By: [Signature]  
Name: Andrew W. Boorn  
Title: President


APPLIED BIOSYSTEMS/MDS SCIEX  
INSTRUMENTS, by its Partners:

APPLIED BIOSYSTEMS (CANADA)  
LIMITED (General Partner)

By:   
Name: ~~John Lauman~~ Dennis L. Winger  
Title: President

MDS Inc., through its business unit  
MDS ANALYTICAL TECHNOLOGIES,  
formerly MDS Sciex (General Partner)

By:   
Name: Andrew W. Boorn  
Title: President

Approved MDS Sciex  
Legal Department  
by:   
date: Nov 20, 2009

DNK\_TIGR2800M-01165/1763808 5

RECORDED: 10/18/2010

0887

RECORDED: 07/27/2015

TRADEMARK  
REEL: 005585 FRAME: 0335